APM - Aptorum files for early-stage trial for ALS-4 in Canada

Aptorum Group (APM) has submitted a Clinical Trial Application with the regulatory authority of Canada, to commence a Phase 1 study evaluating ALS-4 for the treatment of infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus. The 80-subject study will evaluate the safety and tolerability of ALS-4 in healthy subjects and the secondary objective is to assess the pharmacokinetic profile.ALS-4 is an administered small molecule drug based on an anti-virulence (non-antibiotic) for the inhibition of the virulence properties of the bacteria.Shares up 3.8% premarket.

For further details see:

Aptorum files for early-stage trial for ALS-4 in Canada